51. 全身性強皮症 Scleroderma Clinical trials / Disease details
臨床試験数 : 525 / 薬物数 : 565 - (DrugBank : 148) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 217
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2019-001279-34-DE (EUCTR) | 30/09/2019 | 18/07/2019 | A clinical study to test long term safety of GLPG1690 for patients with systemic sclerosis | A multicenter, open-label extension study to evaluate the long-term safety, tolerability and efficacy of orally administered GLPG1690 in subjects with systemic sclerosis | Systemic sclerosis MedDRA version: 20.0;Level: LLT;Classification code 10042953;Term: Systemic sclerosis;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: GLPG1690 Product Code: G451990 INN or Proposed INN: Not applicable Other descriptive name: GLPG1690 | Galapagos NV | NULL | Not Recruiting | Female: yes Male: yes | 30 | Phase 2 | United States;Spain;Belgium;Germany;United Kingdom;Italy | ||
| 2 | EUCTR2019-001279-34-GB (EUCTR) | 20/08/2019 | 24/05/2019 | A clinical study to test long term safety of GLPG1690 for patients with systemic sclerosis | A multicenter, open-label extension study to evaluate the long-term safety, tolerability and efficacy of orally administered GLPG1690 in subjects with systemic sclerosis | Systemic sclerosis MedDRA version: 21.0;Level: LLT;Classification code 10042953;Term: Systemic sclerosis;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: GLPG1690 Product Code: G451990 INN or Proposed INN: ziritaxestat Other descriptive name: GLPG1690 | Galapagos NV | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 30 | Phase 2 | United States;Spain;Belgium;Germany;Italy;United Kingdom | ||
| 3 | EUCTR2019-001279-34-ES (EUCTR) | 13/08/2019 | 11/06/2019 | A clinical study to test long term safety of GLPG1690 for patients with systemic sclerosis | A multicenter, open-label extension study to evaluate the long-term safety, tolerability and efficacy of orally administered GLPG1690 in subjects with systemic sclerosis | Systemic sclerosis MedDRA version: 20.0;Level: LLT;Classification code 10042953;Term: Systemic sclerosis;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: GLPG1690 Product Code: G451990 INN or Proposed INN: Not applicable Other descriptive name: GLPG1690 | Galapagos NV | NULL | Not Recruiting | Female: yes Male: yes | 30 | Phase 2 | United States;Belgium;Spain;Germany;United Kingdom;Italy | ||
| 4 | EUCTR2018-001817-33-BE (EUCTR) | 05/04/2019 | 23/01/2019 | A clinical study to test how effective and safe GLPG1690 is for patients with Systemic Sclerosis | A Phase 2a randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, and tolerability of orally administered GLPG1690 for 24 weeks in subjects with systemic sclerosis | Systemic sclerosis MedDRA version: 20.0;Level: LLT;Classification code 10042953;Term: Systemic sclerosis;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: GLPG1690 Product Code: G451990 INN or Proposed INN: Not applicable Other descriptive name: GLPG1690 | Galapagos NV | NULL | Not Recruiting | Female: yes Male: yes | 30 | Phase 2 | United States;Spain;Belgium;Germany;United Kingdom;Italy | ||
| 5 | EUCTR2018-001817-33-DE (EUCTR) | 29/03/2019 | 23/01/2019 | A clinical study to test how effective and safe GLPG1690 is for patients with Systemic Sclerosis | A Phase 2a randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, and tolerability of orally administered GLPG1690 for 24 weeks in subjects with systemic sclerosis | Systemic sclerosis MedDRA version: 21.0;Level: LLT;Classification code 10042953;Term: Systemic sclerosis;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: GLPG1690 Product Code: G451990 INN or Proposed INN: Not applicable Other descriptive name: GLPG1690 | Galapagos NV | NULL | Not Recruiting | Female: yes Male: yes | 30 | Phase 2 | United States;Spain;Belgium;Germany;United Kingdom;Italy | ||
| 6 | EUCTR2018-001817-33-GB (EUCTR) | 14/01/2019 | 20/11/2018 | A clinical study to test how effective and safe GLPG1690 is for patients with Systemic Sclerosis | A Phase 2a randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, and tolerability of orally administered GLPG1690 for 24 weeks in subjects with systemic sclerosis | Systemic sclerosis MedDRA version: 21.0;Level: LLT;Classification code 10042953;Term: Systemic sclerosis;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: GLPG1690 Product Code: G451990 INN or Proposed INN: Not applicable Other descriptive name: GLPG1690 | Galapagos NV | NULL | Not Recruiting | Female: yes Male: yes | 30 | Phase 2 | United States;Spain;Belgium;Germany;Italy;United Kingdom |